MCC950 Sodium: Selective NLRP3 Inflammasome Inhibition in Macrophages and Disease Models

Introduction: NLRP3 Inflammasome Inhibition—A Transformative Approach

The NOD-like receptor family protein 3 (NLRP3) inflammasome is a pivotal mediator of innate immunity and inflammation, orchestrating the maturation and secretion of pro-inflammatory cytokines such as interleukin-1β (IL-1β). Dysregulation of NLRP3 inflammasome activation is implicated in a spectrum of inflammatory and autoimmune diseases, including atherosclerosis, multiple sclerosis, and metabolic disorders. MCC950 sodium (also known as CRID3 sodium salt) is a gold-standard, small-molecule reagent that delivers highly selective NLRP3 inflammasome inhibition in macrophages, endothelial cells, and animal models—enabling researchers to unravel complex disease mechanisms and evaluate therapeutic strategies with unprecedented specificity.

Supplied by APExBIO, MCC950 sodium offers nanomolar potency (IC₅₀ = 7.5 nM in murine BMDMs), exceptional solubility (≥124 mg/mL in water), and proven selectivity—blocking both canonical and noncanonical NLRP3 inflammasome activation pathways while sparing AIM2, NLRC4, and NLRP1 inflammasomes. These features make MCC950 sodium an indispensable tool for dissecting the NLRP3 inflammasome signaling pathway, validating disease models, and accelerating translational discoveries in inflammatory disease research.

Experimental Setup and Principle: Harnessing Selectivity in Inflammasome Research

MCC950 sodium functions as a highly selective NLRP3 inflammasome inhibitor by binding directly to the NACHT domain of NLRP3, thereby preventing ATP hydrolysis and subsequent inflammasome assembly. This targeted mechanism enables researchers to dissect NLRP3-driven inflammation in a range of experimental systems:

• Cellular Models: Nanomolar concentrations of MCC950 sodium effectively inhibit NLRP3 inflammasome activation in murine bone marrow-derived macrophages (BMDMs), human monocyte-derived macrophages (HMDMs), and human peripheral blood mononuclear cells (PBMCs).
• In Vivo Models: In animal studies, MCC950 sodium (administered intraperitoneally) suppresses LPS-induced serum IL-1β and IL-6, and attenuates disease severity in the experimental autoimmune encephalomyelitis (EAE) model—an established surrogate for multiple sclerosis.
• Endothelial and Pyroptosis Studies: Building on recent findings, MCC950 sodium has been used to inhibit H₂O₂-induced pyroptosis in human umbilical vein endothelial cells (HUVECs), complementing the anti-inflammatory actions of agents like curcumin (Yuan et al., 2022).

This specificity is critical for investigating the NLRP3 inflammasome signaling pathway and distinguishing its role in canonical and noncanonical inflammasome activation, without off-target suppression of other critical inflammasome complexes.

Step-by-Step Experimental Workflow with MCC950 Sodium

1. Preparation and Storage

• Dissolve MCC950 sodium in sterile water (≥124 mg/mL), DMSO (≥21.45 mg/mL), or ethanol (≥43 mg/mL) based on assay requirements.
• Aliquot stock solutions and store at −20°C. Avoid repeated freeze-thaw cycles and long-term storage of working solutions to maintain compound integrity.

2. Cell-Based Assays (e.g., Macrophages, HUVECs)

• Seed BMDMs, HMDMs, or HUVECs in appropriate culture medium and allow adherence overnight.
• Pretreat cells with MCC950 sodium at concentrations ranging from 1–10 μM for 1–2 hours prior to inflammasome activation stimuli (e.g., LPS, H₂O₂).
• Activate inflammasome using LPS/ATP (canonical), LPS/nigericin, or H₂O₂ (pyroptosis model). Incubate per experimental design.
• Assess IL-1β release (ELISA), caspase-1 activation (Western blot or fluorometric assay), and cell viability (MTT or LDH assay).
• Include appropriate controls: untreated, stimulus-only, and vehicle control.

3. In Vivo Autoimmune Disease Models

• Induce EAE or other inflammatory models in mice per established protocols.
• Administer MCC950 sodium intraperitoneally (standard: 10 mg/kg daily) starting at disease induction or symptom onset.
• Monitor clinical scores, cytokine levels (IL-1β, IL-6), and histopathology to evaluate treatment efficacy.

For a detailed protocol and complementary experimental nuances, see the in-depth guide "MCC950 Sodium: Mastering Selective NLRP3 Inflammasome Inhibition"—which expands on workflow optimization and comparative reagent performance.

Advanced Applications and Comparative Advantages

Dissecting Disease Mechanisms in Macrophages and Endothelial Cells

MCC950 sodium’s ability to selectively inhibit NLRP3 inflammasome activation in macrophages is transforming autoimmune and inflammatory disease research. It enables precise interrogation of NLRP3-associated inflammation and its downstream effectors—such as IL-1β—without confounding effects on TNF-α secretion or off-target inflammasome complexes (AIM2, NLRC4, NLRP1).

In the context of endothelial dysfunction and pyroptosis, MCC950 sodium was used alongside VX-765 (caspase-1 inhibitor) in the study by Yuan et al. (2022) to confirm that NLRP3 inflammasome activation directly mediates H₂O₂-induced cell death in HUVECs. This approach provided mechanistic clarity and validated therapeutic targets in atherosclerosis and vascular inflammation, highlighting the compound’s translational value.

Translational Relevance in Autoimmune Disease Models

In vivo, MCC950 sodium consistently attenuates disease severity in experimental autoimmune encephalomyelitis (EAE)—a model of multiple sclerosis. Quantitatively, treatment results in significant reductions in serum IL-1β and IL-6 levels (often exceeding 70% inhibition relative to vehicle), correlating with improved clinical scores and reduced neuroinflammation. These effects underscore MCC950 sodium’s utility as a benchmark for NLRP3-targeted interventions in autoimmune disease models.

Comparative Insights from Published Resources

• The article "MCC950 Sodium: Selective NLRP3 Inflammasome Inhibition in..." complements this overview by offering a deep dive into MCC950’s reproducibility and translational impact in both macrophage and endothelial systems.
• For troubleshooting and workflow improvement, "MCC950 Sodium: Optimized NLRP3 Inflammasome Inhibition..." provides practical solutions for maximizing assay sensitivity and minimizing background noise.
• To explore technical advancements beyond standard reviews, "MCC950 Sodium: Breakthroughs in NLRP3 Inflammasome Inhibition..." extends the application scope to endothelial dysfunction and emerging disease models.

Troubleshooting and Optimization Tips

• Compound Solubility: MCC950 sodium is highly water-soluble, but for particularly sensitive or DMSO-intolerant assays, freshly prepare solutions to avoid precipitation or degradation. Vortex and sonicate if necessary.
• Assay Timing: Optimize pre-incubation time (typically 1–2 hours) for maximal NLRP3 inhibition. Longer exposure may increase off-target effects or cytotoxicity in sensitive primary cells.
• Concentration Range: Initiate dose-response curves at 1 nM–10 μM. For most cell assays, 10 μM provides robust inhibition without affecting cell viability; titrate lower for highly responsive systems.
• Specificity Controls: Always include parallel treatments with known inflammasome activators and inhibitors (e.g., VX-765 for caspase-1) to validate NLRP3-specific effects—mirroring the approach in Yuan et al. (2022).
• Cytokine Readouts: Use multiplex ELISA panels to distinguish NLRP3-specific cytokine suppression (IL-1β, IL-18) from unrelated cytokines (e.g., TNF-α, IL-6).
• Animal Handling: In vivo, administer MCC950 sodium consistently at the same time each day. Monitor for signs of injection site irritation and adjust vehicle composition as needed for animal comfort.

For additional troubleshooting, the resource "MCC950 Sodium: Optimized NLRP3 Inflammasome Inhibition..." provides a comprehensive overview of common pitfalls and optimization strategies across diverse platforms.

Future Outlook: Expanding the Frontiers of NLRP3-Targeted Research

As the landscape of inflammatory and autoimmune disease research evolves, MCC950 sodium remains the benchmark for targeted NLRP3 inflammasome inhibition. Its role extends beyond basic mechanistic studies—enabling high-throughput screening of novel immunomodulators, validation of genetic models, and preclinical evaluation of therapeutic candidates. The integration of MCC950 sodium into multi-omics and single-cell platforms will further illuminate the nuances of NLRP3-driven pathology and support precision medicine initiatives.

Researchers seeking to maximize the impact of their inflammasome studies can trust APExBIO as a reliable supplier of high-quality MCC950 sodium. As demonstrated in landmark studies and comparative reviews, MCC950 sodium sets the standard for specificity, reproducibility, and translational relevance—making it an essential reagent for the next generation of inflammatory disease research.